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Investigation (In Vivo and In Vitro) of Booster Dose
Vaccine Requirement for Long-Term Protection against
Hepatitis B Virus Infection*
Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination
for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster
dose requirement for HBV after primary immunization was investigated.
Materials and Methods: Seventeen individuals vaccinated previously were enrolled in the study. They had
once developed a protective level of anti-HBs antibody after immunization and their anti-HBs titer had declined
to an underprotective level. Twenty uninfected and unvaccinated healthy people were chosen as controls.
Lymphoproliferative response to in-vitro stimulation with hepatitis B surface antigen (HBsAg) and anti-HBs
response to vaccine were evaluated for immune response.
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Results: T lymphocytes from 4 (24%) of the study group showed lymphoproliferative response to HBsAg
stimulation while none of the controls did (P < 0.05). In all subjects in the study group, anti-HBs response
(≥10 mIU/ml) was detected 1 to 7 days after the booster injection but in only 2 of the controls antibody
response was detected 28 days after the first dose of HBV vaccine (P < 0.0001).
Conclusions: A booster dose of HBV vaccine might not be required because of immunological memory.
Key Words: HBV vaccination, long-term protection, booster dose requirement, immunological memory

Hepatit B Virüsüne Karşı Aşılamada Uzun Süreli Korunma için Booster Doz
Gerekliliğinin (İn Vivo ve İn Vitro) Araştırılması
Amaç: Çalışmalar; primer aşılamadan sonra antikor gelişen kişilerde en az 10-15 yıl süre ile booster doza
ihtiyaç olmadığını göstermiştir. Bu çalışmada; primer aşılamadan sonra booster doza gereksinim
araştırılmıştır.
Yöntem ve Gereç: Daha önce aşılanmış 17 kişi çalışmaya alındı. Bu kişilerde primer aşılamadan sonra antiHBs oluşmuş ve zamanla anti-HBs titresi koruycu düzeyin altına düşmüştü. Kontrol grubu olarak, enfekte
olmamış ve aşılanmamış 20 kişi seçildi. Hücresel yanıtı araştırmak için, T lenfositlerin in-vitro HBsAg uyarısına
karşı oluşturduğu lenfoproliferatif yanıt, ve aşı sonrası oluşan antikor yanıtı değerlendirildi.
Bulgular: Kontrol grubundakilerin hiçbirinde HBsAg uyarısına karşı yanıt görülmezken, çalışma grubundaki
4 kişide (% 24) T lenfositlerde lenfoproliferatif yanıt görüldü (P < 0,05). Çalışma grubunda booster dozdan
1-7 gün içinde antikor yanıtı oluşurken, kontrol grubundakilerin sadece ikisinde booster aşı dozu sonrası 28.
günde antikor yanıtı oluştu (P < 0,0001).
Sonuç: İmmünolojik memori sayesinde booster HBV aşısı dozuna gereksinim olmayabilir.
Anahtar Sözcükler: HBV aşısı, uzun süreli korunma, booster doz gerekliliği
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Hepatitis B virus (HBV) is the most frequent and the unique vaccine preventable
cause of chronic viral hepatitis (1-5).
The standard application schedule for the HBV vaccine consists of 3 doses
administered at 0, 1, and 6 months. For individuals at high risk of infection, another
schedule consisting of 4 doses administered at 0, 1, 2, and 12 months is recommended
(6-8).
* Presented at the Biennial Meeting of IASL-2002.
Awarded (3rd degree) in National Congress on Viral Hepatitis in 2006.
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A higher anti-HBs antibody level after primary
vaccination suggests a longer duration of protective
immunity. The results of mass vaccination studies showed
that most individuals (70% to 90%) responded well to
primary vaccination, preserving their antibody at
protective levels ( 10 mIU/ml) up to 10 to 12 years. AntiHBs antibody level in some of the individuals vaccinated
might decline to undetectable levels in 5 to 10 years. In
such a situation, whether the protection continues or not
is debatable. No case of clinical HBV infection among
individuals to whom a primary vaccination schedule was
applied has been reported, but there are a few reported
cases of HBsAg carrier state (9-13).
Owing to immunological memory function, immune
response to secondary immunization is more rapid and
stronger than that to primary immunization (14).
Therefore, periodic booster dose vaccine administration
to individuals once fully vaccinated might not be required.
In this study, we aimed to show the immune response
to HBV vaccine (in vivo and in vitro) in subjects vaccinated
before and whose antibody levels declined below 10
mIU/ml and to determine if a periodic booster dose of
vaccination was required.

Materials and Methods
This study was carried out in Gülhane Military Medical
Academy (GMMA) Department of Infectious Diseases and
Clinical Microbiology and Department of Immunology.
In 1997, serological screening (HBsAg, anti-HBc-IgG
and anti-HBs) was performed by the Department of
Infectious Diseases and Clinical Microbiology among
health care workers (HCWs) working for GMMA training
hospital. Records of 2184 individuals were reevaluated
and we got in contact with subjects whose serological test
results for HBV (HBsAg, anti-HBc IgG, and anti-HBs)
were all negative. They were asked if they had been
vaccinated with HBV vaccine and, if so, when and how
many doses had been administered. They were also asked
if they had anti-HBs antibody response. Seventeen
individuals who were fully vaccinated, who developed
anti-HBs antibody and whose anti-HBs antibody titer
declined under 10 mIU/ml were enrolled in the study. Of
these 17 individuals, 8 were male and 9 female.
Twenty healthy unvaccinated HCWs not exposed to
HBV (i.e. negative for anti-HBc IgG) and whose age and
174
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sex were consistent with the study group were chosen as
controls.
The study was designed as in vitro for cellular immune
response evaluation and as in vivo for humoral immune
response evaluation.
For in vitro cellular immune response evaluation, in
sterile conditions 10 ml of heparinized venous blood was
drawn from all individuals in both groups. The blood
samples were centrifuged at 1500 rpm for 10 min and
plasma from each sample was extracted. The same
amounts of cell culture medium and plasma were mixed
and then the mixture was layered on Histopaque (SIGMA,
USA). After that, the mixture was centrifuged at 1500
rpm for 10 min. Interphase mononuclear cells were
extracted and washed with 5 ml of cell culture medium 3
times. Amount of cells was standardized as 2 × 106
cells/ml and these cells were cultivated in a microplate
5
with autologous plasma, 10 cells in each well. For
investigating immune response to HBsAg, HBsAg was
added until the final concentration reached 5 mg/ml. The
cells were incubated for 72 h at 37 °C in an incubator
containing 5% CO2 and 95% dry air. Soon after, 0.5 mCi
3
H-Timidin (Amersham, UK) was added to each well and
the plate was incubated for 18 h in the same incubator.
After incubation, the cells were collected by a harvester
and the amount of radioactive timidine was counted by a
b-counter as counts per minute (cpm). The results of the
counts were determined according to the mean of the
counts of triple wells. The stimulation index was
calculated by dividing the counts in medium with HBsAg
and without HBsAg. The stimulation index higher than
twice the standard deviation amount of the mean
stimulation index of controls was considered positive for
proliferative response.
For in vivo humoral immune response evaluation, 20
μg/ml of recombinant HBV vaccine (EUVAX B, North
Korea) was administered to the deltoid region of all
subjects intramuscularly. Blood was drawn from
individuals in the study group 1, 3, 5, 7, 14, and 28 days
after vaccination. Since anti-HBs response was not
expected to develop in the first week of vaccination (15),
blood was drawn from individuals in the control group
only 7, 14, and 28 days after the first dose of vaccine was
administered. Then the HBV vaccination schedule was
completed in the control group. The blood drawn was
centrifuged immediately and sera were stored at –85 °C
until the anti-HBs assay was performed. The stored
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samples were thawed and anti-HBs titers were detected
by EIA (Abbott/Murex, Germany) by an automated EIA
device (Tecan, Italy) according to the procedure
suggested by the manufacturer. A titer less than 10
mIU/ml was considered negative, between 10 and 99
mIU/ml positive, and over 100 mIU/ml highly positive.
The number of subjects who developed protective
antibodies was given as a percentage for the study group
on days 1, 3, 5, 7, 14, and 28 after the booster dose of
HBV vaccine, and for the control group on the days 7, 14,
and 28 after the first dose of HBV vaccine. Statistical
analysis was performed using Excel for Windows
(Microsoft, USA).

Results
Of the 17 subjects in the study group (mean age:
30.47 ± 8.36 years and range: 18 to 47), 8 (47.05%)
were male and 9 (52.95%) female. Of the control group
(mean age: 30.2 ± 7.65 years and range: 18 to 45), 10
(50%) were male and 10 (50%) female. There was no
significant difference between the study group and the
control group in terms of their demographic
characteristics (age, sex, obesity, body mass index,
cigarette smoking and alcohol abuse, systemic illnesses,
etc.) (P > 0.05).
In the in vitro investigation of cellular immunity, no
lymphoproliferative response to HBsAg stimulation was
observed in the control group but peripheral mononuclear
cells from 4 (23.53%) individuals in the study group
showed lymphoproliferative response (P < 0.05).
In the in vivo investigation of humoral immunity, just
24 h after the injection of booster HBV vaccine,
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protective anti-HBs antibody developed in 7 (41.17%) of
the subjects, and on the other days the numbers of
subjects who developed protective anti-HBs antibody
were as follows: 10 (58.82%), 14 (82.35%), and 17
(100%) on days 3, 5, and 7, respectively.
The number of subjects who developed high
protective ( 100 mIU/ml) anti-HBs antibody response was
2 (11.76%) on day 1 and was 3 (17.64%), 6 (35.29%),
8 (47.05%), 14 (82.35%), and 16 (91.11%) 3, 5, 7,
14, and 28 days after the booster dose of HBV vaccine,
respectively.
No anti-HBs antibody response was observed in the
control group in the first 2 weeks after the first vaccine.
Only 2 (10%) of them had anti-HBs antibody on day 28.
There was a significant difference between the study
and control groups in terms of their anti-HBs levels on
day 28 of vaccination (P < 0.0001). The results of the in
vivo investigation of humoral immunity are given in the
Table.

Discussion and Conclusion
In 1981, plasma-derived HBV vaccine and, in 1996,
recombinant HBV vaccine became commercially available.
In those years, a routine booster dose of HBV vaccine was
recommended in each 5-year period after the primary
vaccination. However, nowadays, requirement for
booster dose of HBV vaccine for life-long immunity is
debated and it is suggested that even if a protective
amount of anti-HBs antibody is not detected in serum
samples of pre-vaccinated individuals, owing to
immunological memory, protection still exist (16).

Table. The results of in vivo investigation of humoral immunity.
Subjects Developed
Anti-HBs Antibody 10 mIU/ml

Subjects Developed
Anti-HBs Antibody 100 mIU/ml

Days after HBV Vaccine

1
3
5
7
14
28

Study Group
n/%

Control Group
n/%

Study Group
n/%

Control Group
n/%

7 / 41.17
10 / 58.82
14 / 82.35
17 / 100
17 / 100
17 / 100

0/0
0/0
2 / 10

2 / 11.76
3 / 17.64
6 / 35.29
8 / 47.05
14 / 82.35
16 / 91.11

0/0
0/0
2 / 10
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Both cellular immunity and humoral immunity play
roles in immunological memory. However, most studies
performed were based on B lymphocyte function
evaluation. There are few studies based on T lymphocyte
function evaluation.
In our study, we observed lymphoproliferative response
in 24% (4/17) of the subjects in the study group. This
result was lower than we expected but it was significantly
higher than that in the control group (P < 0.05).
Huang et al. evaluated immunological memory in prevaccinated subjects comparing T cell lymphoproliferative
response, IL-2 and IL-5 production of T lymphocytes, and
anti-HBs antibody production of B lymphocytes before
and a month after a booster dose of HBV vaccine. In their
study, they detected T lymphocyte lymphoproliferative
response in 47%, IL-2 response in 81%, and IL-5
response in 100% of the subjects, and, after the booster
HBV vaccine injection, they detected T lymphocyte
lymphoproliferative response in 52%, IL-2 response in
90%, and IL-5 response in 100% of subjects. Injection of
HBV vaccine augmented T lymphocyte proliferative
response and IL-2 production of T lymphocyte, but these
increases were not significant. They also reported that IL5 was the most predictive marker of immunological
memory (17).
Leroux et al. activated T lymphocytes and observed
their clonal proliferation. They reported that humoral
immune response kinetics to antigenic stimulation was
closely related to T cell response (18).
Nagaraju et al. observed lymphoproliferative response
in only 3 (10.34%) of 29 pre-vaccinated cases but they
detected sufficient amounts of antibody in all cases after
a booster dose of HBV vaccine (19).
We also evaluated in vivo anti-HBs antibody response
to a booster dose of HBV vaccine for B lymphocyte
function and we achieved significant results. All subjects
in the study group developed protective levels of anti-HBs
antibody in the first 7 days but none in control group did
until 14 days after the first vaccine (P < 0.0001). We
suggested that this result was due to immunological
memory.
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Jilg et al. administered a booster dose of HBV vaccine
and detected anti-HBs antibody level of 10 mIU/ml in
96% of 212 pre-vaccinated individuals who had
responded to primary vaccination. They also detected
anti-HBs antibody on days 3 to 5 of the booster injection
in 4 individuals who had responded to primary
vaccination but had no antibody detected at the time of
booster injection. As a result, they reported
immunological memory extended protection even if no
antibody had been detected in individuals vaccinated
before (20).
Krugman et al. (21), Milne et al. (22,23), and West et
al. (13) reported the existence of immunological memory
based on anti-HBs antibody response to a booster dose of
HBV vaccine.
Boland et al. detected circulating B lymphocytes
producing anti-HBs, using specific spot-ELISA test in 68%
of 37 individuals whose antibody level was under 10 mIU/ml
in 6-8 years after primary vaccination and they reported
that protection against HBV continued also in individuals in
whom anti-HBs antibody was not detected (24).
We used recombinant vaccine in our study. Because
both plasma-derived and recombinant vaccines were
immunogenic and effective (25-30), we did not compare
the types of vaccine administered in primary vaccination.
In addition, as vaccination schedule and dosage used in
primary vaccination had no effect on immunological
memory (6-8,17) we ignored these differences in our
study.
Although the fact that anamnestic response develops
in a very short time is encouraging, it is not possible to
conclude there is no risk of infection until antibody
develops, since the duration for HBV to reach hepatocytes
is not well established.
Our study implied that immunological memory went
on working in individuals whose anti-HBs antibody levels
became undetectable and we concluded that primary HBV
vaccination with no booster injection might be regarded
as long-life preventive, but it is obvious that this
prediction is valid for only immunocompetent and lowrisk individuals.
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